MILAN--(BUSINESS WIRE)--Sorin Group, (MIL:SRN), a global company and a leader in the treatment of cardiovascular diseases, announced today that the Board of Directors has examined the request to conduct due diligence, received on March 22, 2010 from a consortium composed of Ares Life Sciences AG, Essex Woodlands Health Ventures UK Ltd, Intesa SanPaolo S.p.A. e Alpha Private Equity Funds (‘Consortium’). The Consortium has indicated that it is in exclusive negotiations with Mittel S.p.A. and Equinox Two S.c.A..
